Cipla stock increases; US FDA examination concludes with zero observations
Cipla stock: On March 2nd, Cipla’s stock experienced a notable uptick, marking a gain of 1.43 percent. This surge brought it tantalizingly close, just Rs 2 away, from reaching the 52-week high it had achieved in the preceding session. From February 26 to March 1, the US Food and Drug Administration (USFDA) examined a production…